🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Application of FET-PET in Fusion With MRI in the Treatment of Glioblastoma Multiforme [TYR-GLIO]

RecruitingNAAges 18 Years - 70 YearsAllCopernicus Memorial Hospital
NCT06466031 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Glioblastoma multiforme (GBM WHO IV) is the most common and aggressive primary brain tumor in adults, carrying a poor prognosis with a median survival of 12-16 months. The annual incidence is approximately 5 per 100,000 (roughly 600 cases annually in Poland), predominantly affecting individuals in their prime productive years. The standard of care consists of maximal safe resection followed by the Stupp protocol (60 Gy fractionated radiotherapy and temozolomide chemotherapy). Routine surgical management relies on contrast-enhanced MRI. Gross total resection (GTR) is defined as the complete removal of the contrast-enhancing lesion. Although GTR improves progression-free survival (PFS) and overall survival (OS), local recurrence at the operative site occurs in up to 51% of patients within a year. This rapid regrowth is driven by glioblastoma stem cells infiltrating the surrounding non-enh

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Single macroscopic tumor focus with the appearance of glioblastoma multiforme on MRI with contrast - contrast-enhancing lesion, completely or with central necrosis, with surrounding edema. * No history of cancer in other organs. No suspicious lesions on X-ray of the chest and abdomen (CT with contrast). * No clinical suspicion of brain abscess - no meningeal symptoms, signs of neuroinfection, fever, elevated inflammatory parameters. * Primary tumor, without neurosurgical, radiotherapy or oncology intervention. Prior tumor biopsy is allowed. * Tumor eligible for surgical treatment - craniotomy and tumor resection. * Age ≥ 18 years but \< 70 years old. * Quality of life assessment: KPS ≥ 70. * Informed patient consent to the study and proposed treatment. * No allergy to contrast agents used in PET and MRI. * No medical contraindications to neurosurgery - craniotomy and resection. Exclusion Criteria: * Multifocal brain tumor. * Recurrence of glioblastoma multiforme. * Clinical or radiological suspicion of brain metastasis or brain abscess. * Postoperative histopathological diagnosis other than WHO grade IV glioblastoma. * Medical contraindications to any surgery under general anesthesia. * Pregnancy, breastfeeding. * Known allergy to gadolinium contrast or radiopharmaceutical tracing agent.
💊

What it tests

  • MRI & PET fusion
  • MRI+T1C
📍

Where

1 site
Copernicus Memorial Hospital in Łódź, Poland
Lodz, Poland
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy